Lebel will be responsible for leading the Spectrum clinical program which includes directing the clinical research staff, overseeing the company's ongoing clinical trials, and regulatory submissions.
He will also direct clinical development strategies, life-cycle management, relationships with regulatory bodies and provide strategic counsel on all business development activities.
Lebel brings nearly 30 years of clinical leadership experience within the biopharmaceutical industry. He has designed and managed global medical organisations to deliver results, enhance productivity and practice sound risk management.
Most recently, he served as the executive vice president of Research and Development, Chief Medical officer at Ziopharm Oncology.
He also held various leadership roles including vice president of research and cevelopment at Baxter International and global head of medical and scientific affairs at MedImmune.
In the last 25 years, he provided strategic leadership on eight NDA/BLAs in various therapeutic areas and on a number of mergers and acquisitions.
Lebel has broad and deep experience in oncology drug development, medical affairs, regulatory and pharmacovigilance acquired through various roles of increasing responsibilities at Chiron (Novartis), Warner-Lambert (Pfizer) and Burroughs Wellcome.
He received his medical degree from the University of Ottawa, Canada, and he completed his post graduate training at McGill University and Harvard Medical School. He is Board Certified in Internal Medicine and a fellow of the Royal College of Physicians of Canada.
Spectrum Pharmaceuticals is a biopharmaceutical company focused on acquiring, developing, and commercializing drug products, with a primary focus in hematology and oncology.
The company currently markets six hematology/oncology drugs, and has an advanced stage pipeline that has the potential to transform the company.
Spectrum's strong track record for in-licensing and acquiring differentiated drugs, and expertise in clinical development have generated a robust, diversified, and growing pipeline of product candidates in advanced-stage Phase 2 and Phase 3 studies.
GSK announces positive EAGLE-1 results for gepotidacin in gonorrhoea treatment
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
Charles River Laboratories launches AMAP to reduce animal testing reliance
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
GSK's meningitis vaccine candidate accepted for FDA review
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
AbbVie announces interim evaluation of Atogepant Phase three, open-label 156-week extension study